Th-227-Epratuzumab (Th-227-BAY1862864)

²²⁷Th-Epratuzumab (²²⁷Th-BAY1862864 is a CD-22 thorium conjugate targeting relapsed or refractory CD-22 positive non-Hodgkin’s lymphoma. This molecule is in priority developed for the treatment of relapsed or refractory CD-22 positive non-Hodgkin Lymphoma.

²²⁷Th-BAY1862864 has entered phase I/II clinical trial in November 2015 (60 patients to be enrolled). This study was completed by end of 2019. No further clinical study was initiated since.

Target/Mechanism: CD-22

Leading Emitter: Alpha particle (α)